News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RXi Pharmaceuticals (RXII) Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors



4/22/2013 6:32:10 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that H. Paul Dorman and Curtis Lockshin, Ph.D. have been appointed to the Company’s Board of Directors. Mr. Dorman and Dr. Lockshin both bring significant industry experience that will be instrumental to supporting RXi’s growth and development initiatives.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES